Autres langues Zai Lab Limited

Actions

ZLAB

US98887Q1040

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:00:56 26/06/2026			Varia. 5j.	Varia. 1 janv.
17,71 ^USD	-4,37%		-5,98%	-1,50%

16/06	Zai Lab obtient le statut de médicament orphelin dans l'UE pour son traitement contre le cancer du poumon	MT
10/06	Les actions asiatiques cotées aux États-Unis sous forme d'ADR s'inscrivent en baisse lors de la séance de mercredi	MT

Autres langues

17/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas
16/06	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug
16/06	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
10/06	Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
09/06	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment
09/06	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer
09/06	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
29/05	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
22/05	Zai Lab President, COO Josh Smiley to Depart
22/05	Zai Lab Ousts COO Josh Smiley
22/05	Zai Lab Announces Changes to Senior Leadership Team
22/05	Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026
19/05	Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing
18/05	Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
15/05	Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing
15/05	Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
11/05	Zai Lab Limited Receives FDA Fast Track Designation for Zocilurtatug Pelitecan for Treatment of Extrapulmonary Neuroendocrine Carcinomas
11/05	Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
11/05	Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas
11/05	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
08/05	Asian Equities Traded in the US as American Depositary Receipts Edge Higher Friday
08/05	Zai Lab's Net Loss Widens in Q1
07/05	Zai Lab Q1 Loss Widens, Revenue Falls
07/05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q1 Revenue $99.6M, vs. FactSet Est of $108.4M
07/05	Earnings Flash (ZLAB) Zai Lab Limited Reports Q1 Loss of $0.46 per ADS, vs. FactSet Est of $-0.54